drugset / Trial / NCT01538966
Acromegaly Combination Treatment Study
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily pegvisomant will attain equivalent control of serum insulin-like growth factor (IGF)-1 levels at a lower cost, compared to combination high dose SRL and weekly pegvisomant. Lower doses of therapy will greatly reduce cost of acromegaly therapy.
Timeline
- Start
- 2012-03-29
- Primary completion
- 2022-05-20
- Completion
- 2022-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lanreotide | Other / unclassified | 60 mg | — |
| Comparator | Lanreotide | Other / unclassified | 120 mg | — |
| Comparator | Octreotide | Peptide | 10 mg | — |
| Comparator | Octreotide | Peptide | 30 mg | — |
| Comparator | Pegvisomant | Protein / enzyme biologic | 15 mg | — |
| Comparator | Pegvisomant | Protein / enzyme biologic | 40 mg | — |
| Comparator | Pegvisomant | Protein / enzyme biologic | 60 mg | — |
| Comparator | Pegvisomant | Protein / enzyme biologic | 120 mg | — |